Compose: Pivotal Phase III Trial of Lu-177-Edotreotide Versus Best Standard of Care in Well-Differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuroendocrine TumorsThorvardur R. Halfdanarson,Diane Reidy,Namrata Vijayvergia,Daniel Halperin,Grace Goldstein,Grace Kong,Michael Michael,Simone Leyden,Simona Grozinsky-Glasberg,Halfdan Sorbye,Kjell Oberg,Thomas Thevenet, Martina Christine HerrmannPANCREAS（2022）引用 0|浏览12暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
